Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.
TYK2, a Janus kinase family member, mediates signaling from pro-inflammatory cytokines such as type I interferons, IL-12 and IL-23. In multiple sclerosis (MS), chronic CNS inflammation involves glial activation and immune cell infiltration, making TYK2 inhibition a potential strategy to reduce neuroinflammation.
TMEM97 regulates microglial activation and neuronal stress pathways linked to neuropathic pain and neuroinflammation in multiple sclerosis (MS). Pharmacological targeting of TMEM97 has shown neuroprotective effects in models of traumatic brain injury, Huntington’s disease and retinal ganglion cell degeneration, and may reduce pain while preserving neuronal function.
